

STATEMENT OF PURPOSE

RS25291

This bill amends the definition of the practice of pharmacy to increase patient access to certain categories of medications that are low risk, if used under the supervision of a pharmacist. Specifically, it would allow the Board of Pharmacy to designate by rule products that patients may obtain directly from a pharmacist for conditions that do not require a diagnosis, conditions that are minor and self-limiting, and conditions that have a simple CLIA-waived laboratory test which guides clinical decision making. Other states have been able to achieve improved health outcomes and lowered overall healthcare costs from similar policies.

FISCAL NOTE

This legislation will have no fiscal impact to the General Fund or the Board of Pharmacy's dedicated fund. It has no fiscal impact because, although this legislation allows the Board of Pharmacy to promulgate rules, it does not compel any specific action from the agency. The Board of Pharmacy already hosts annual negotiated and proposed rulemaking sessions that are open to the public and it is anticipated that any rules promulgated under this bill will occur during those pre-existing meetings.

Contact:

Representative Christy Perry
(208) 332-1000

DISCLAIMER: This statement of purpose and fiscal note are a mere attachment to this bill and prepared by a proponent of the bill. It is neither intended as an expression of legislative intent nor intended for any use outside of the legislative process, including judicial review (Joint Rule 18).